Navigating immunotherapy for ovarian cancer: current landscape and future perspectives

Abstract

Ovarian cancer (OC) is the leading cause of death related to gynecologic malignancies, with recurrence occurring frequently despite significant advances in surgical interventions and chemotherapy. Therefore, novel therapies are necessary to improve the long-term prognosis of the disease. Immunotherapy holds promise in OC treatment by harnessing the potential of the immune system to combat neoplastic cells. The effectiveness of immunotherapy has been demonstrated in numerous cancers and subsequently integrated into clinical practice. However, despite initial preclinical findings suggesting an immunogenic microenvironment in OC, immune checkpoint inhibitors have not shown significant outcomes in clinical studies thus far. Further investigation is needed to fully understand the role of immunity in OC and to develop more effective therapeutic strategies, including combinatorial approaches and the identification of predictive biomarkers for more accurate patient selection for immunotherapy.

Keywords

Ovarian cancer / immunotherapy / immune checkpoint inhibitors / PARP inhibitors / oncolytic viruses / adoptive cell therapy

References

[1] Siegel RL,Jemal A.Cancer statistics, 2018.CA Cancer J Clin2018;68:7-30

[2] Saani I,Sood R.Clinical challenges in the management of malignant ovarian germ cell tumours.Int J Environ Res Public Health2023;20:6089 PMCID:PMC10298722

[3] Bailey M,Royfman R.Targeted combination of poly(ADP-ribose) polymerase inhibitors and immune checkpoint inhibitors lacking evidence of benefit: focus in ovarian cancer.Int J Mol Sci2024;25:3173 PMCID:PMC10970335

[4] Gupta S,Aggarwal S,Warrier N.Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives - a review.J Ovarian Res2019;12:103 PMCID:PMC6827246

[5] Secord A, O’Malley DM, Sood AK, Westin SN, Liu JF. Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: a review.Gynecol Oncol2021;162:482-95

[6] Kurnit KC,Westin SN.Using PARP inhibitors in the treatment of patients with ovarian cancer.Curr Treat Options Oncol2018;19:1 PMCID:PMC8240125

[7] Capuozzo M,Santorsola M.Emerging treatment approaches for triple-negative breast cancer.Med Oncol2023;41:5

[8] Capuozzo M,Santorsola M,Ottaiano A.Circulating tumor cells as predictive and prognostic biomarkers in solid tumors.Cells2023;12:2590 PMCID:PMC10670669

[9] Salmaninejad A,Shabgah AG.PD-1/PD-L1 pathway: basic biology and role in cancer immunotherapy.J Cell Physiol2019;234:16824-37

[10] Akinleye A.Immune checkpoint inhibitors of PD-L1 as cancer therapeutics.J Hematol Oncol2019;12:92 PMCID:PMC6729004

[11] Wakabayashi G,Luh F,Chang WC.Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway.J Biomed Sci2019;26:96

[12] Hamanishi J,Iwasaki M.Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer.Proc Natl Acad Sci USA2007;104:3360-5 PMCID:PMC1805580

[13] Maine CJ,Chatterjee J.Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer.Cancer Immunol Immunother2014;63:215-24 PMCID:PMC11029577

[14] Santoiemma PP.Tumor infiltrating lymphocytes in ovarian cancer.Cancer Biol Ther2015;16:807-20 PMCID:PMC4622931

[15] Sun J,Xu D.Immuno-genomic characterisation of high-grade serous ovarian cancer reveals immune evasion mechanisms and identifies an immunological subtype with a favourable prognosis and improved therapeutic efficacy.Br J Cancer2022;126:1570-80 PMCID:PMC9130248

[16] Wilkinson AN,Coleborn E.Let-7i enhances anti-tumour immunity and suppresses ovarian tumour growth.Cancer Immunol Immunother2024;73:80 PMCID:PMC10981620

[17] Pugh-Toole M,Nersesian S,Boudreau JE.Natural killer cells: the missing link in effective treatment for high-grade serous ovarian carcinoma.Curr Treat Options Oncol2022;23:210-26

[18] Janardhanan M,Rajalakshmi G,Koyakutty M.Tumour microenvironment as a potential immune therapeutic target for tongue cancer management.J Oral Maxillofac Pathol2023;27:382-9 PMCID:PMC10581303

[19] Asadi M,Zafari V.Immune features of tumor microenvironment: a genetic spotlight.Cell Biochem Biophys2024;82:107-18

[20] Das A,Naicker K.Advances in adoptive T-cell therapy for metastatic melanoma.Curr Res Transl Med2023;71:103404

[21] Hamanishi J,Ikeda T.Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer.J Clin Oncol2015;33:4015-22

[22] Nishio S,Takehara K.Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: subgroup analysis from the KEYNOTE-100.Cancer Sci2020;111:1324-32

[23] Duraiswamy J,Freeman GJ.Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.Cancer Res2013;73:3591-603 PMCID:PMC3686913

[24] Duraiswamy J,Coukos G.Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors-response.Cancer Res2014;74:633-4

[25] Chen J,Yao Q.The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis.World J Surg Oncol2020;18:150 PMCID:PMC7334852

[26] Shoushtari AN,Navid-Azarbaijani P.Measuring toxic effects and time to treatment failure for nivolumab plus ipilimumab in melanoma.JAMA Oncol2018;4:98-101 PMCID:PMC5833656

[27] Zamarin D,Sill MW.Randomized phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an NRG oncology study.J Clin Oncol2020;38:1814-23 PMCID:PMC7255977

[28] Wang H,Ho PC.Metabolic regulation of tregs in cancer: opportunities for immunotherapy.Trends Cancer2017;3:583-92

[29] Gao X.Combinations of bevacizumab with immune checkpoint inhibitors in renal cell carcinoma.Cancer J2018;24:171-9

[30] Chen Y,Li D,Zhang L.Atezolizumab and blockade of LncRNA PVT1 attenuate cisplatin resistant ovarian cancer cells progression synergistically via JAK2/STAT3/PD-L1 pathway.Clin Immunol2021;227:108728

[31] Liu JF,Gray KP.Assessment of combined nivolumab and bevacizumab in relapsed ovarian cancer: a phase 2 clinical trial.JAMA Oncol2019;5:1731-8 PMCID:PMC6802049

[32] Pignata S,Sehouli J.Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer.Gynecol Oncol2023;177:20-31 PMCID:PMC10986425

[33] Kurtz JE,Oaknin A.Atezolizumab combined with bevacizumab and platinum-based therapy for platinum-sensitive ovarian cancer: placebo-controlled randomized phase III ATALANTE/ENGOT-ov29 trial.J Clin Oncol2023;41:4768-78

[34] Higuchi T,Marjon NA.CTLA-4 blockade synergizes therapeutically with PARP inhibition in BRCA1-deficient ovarian cancer.Cancer Immunol Res2015;3:1257-68 PMCID:PMC4984269

[35] Lorusso D,Daniele G.Immunotherapy in gynecological cancers.Explor Target Antitumor Ther2021;2:48-64 PMCID:PMC9400773

[36] Stewart RA,Yap TA.Development of PARP and immune-checkpoint inhibitor combinations.Cancer Res2018;78:6717-25

[37] Lee EK.Combined PARP and Immune checkpoint inhibition in ovarian cancer.Trends Cancer2019;5:524-8

[38] Murray JL,Ioannides CG.Clinical trials of HER-2/neu-specific vaccines.Semin Oncol2000;27:71-5

[39] IeM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.Am J Pathol2004;164:1511-8 PMCID:PMC1615664

[40] Ding J,Che Y.Ovarian cancer stem cells: critical roles in anti-tumor immunity.Front Genet2022;13:998220 PMCID:PMC9685611

[41] Hamley IW.Peptides for vaccine development.ACS Appl Bio Mater2022;5:905-44 PMCID:PMC9384901

[42] Capuozzo M,Bocchetti M.p53: from fundamental biology to clinical applications in cancer.Biology2022;11:1325 PMCID:PMC9495382

[43] Hilliard TS.The impact of mesothelin in the ovarian cancer tumor microenvironment.Cancers2018;10:277 PMCID:PMC6162689

[44] Vandin F.Computational methods for characterizing cancer mutational heterogeneity.Front Genet2017;8:83 PMCID:PMC5469877

[45] Szender JB,Eng KH.NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer.Gynecol Oncol2017;145:420-5 PMCID:PMC5497581

[46] Pavlick A,Meseck M.Combined vaccination with NY-ESO-1 protein, Poly-ICLC, and montanide improves humoral and cellular immune responses in patients with high-risk melanoma.Cancer Immunol Res2020;8:70-80 PMCID:PMC6946846

[47] Wada H,Kakimi K.Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.J Immunother2014;37:84-92

[48] Odunsi K,Matsuzaki J.Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer.Proc Natl Acad Sci USA2007;104:12837-42 PMCID:PMC1937553

[49] Srivastava PK.Cancer neoepitopes viewed through negative selection and peripheral tolerance: a new path to cancer vaccines.J Clin Invest2024;134:e176740 PMCID:PMC10904052

[50] Zhang Z,Qin Y.Neoantigen: a new breakthrough in tumor immunotherapy.Front Immunol2021;12:672356 PMCID:PMC8085349

[51] Tu SM,Vellanki S.Stem cell origin of cancer: clinical implications beyond immunotherapy for drug versus therapy development in cancer care.Cancers2024;16:1151 PMCID:PMC10969562

[52] Morisaki T,Onishi H.Intranodal administration of neoantigen peptide-loaded dendritic cell vaccine elicits epitope-specific T cell responses and clinical effects in a patient with chemorefractory ovarian cancer with malignant ascites.Immunol Invest2021;50:562-79

[53] Yu R,Xu Z,Du B.Current status and future of cancer vaccines: a bibliographic study.Heliyon2024;10:e24404 PMCID:PMC10826732

[54] Kverneland AH,Westergaard MCW.Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer.Oncotarget2020;11:2092-105 PMCID:PMC7275789

[55] Rocconi RP,Bottsford-Miller JN.Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer.Cancer Gene Ther2022;29:369-82

[56] Chen L,Xu C.Progress in oncolytic viruses modified with nanomaterials for intravenous application.Cancer Biol Med2023;20:830-55 PMCID:PMC10690878

[57] Feola S,Ylösmäki E.Oncolytic ImmunoViroTherapy: a long history of crosstalk between viruses and immune system for cancer treatment.Pharmacol Ther2022;236:108103

[58] Oh CM,Kim C.Combination immunotherapy using oncolytic virus for the treatment of advanced solid tumors.Int J Mol Sci2020;21:7743 PMCID:PMC7589893

[59] Jin KT,Liu YY,Si JX.Oncolytic virotherapy in solid tumors: the challenges and achievements.Cancers2021;13:588 PMCID:PMC7913179

[60] Hu H,Cai L.A novel cocktail therapy based on quintuplet combination of oncolytic herpes simplex virus-2 vectors armed with interleukin-12, interleukin-15, GM-CSF, PD1v, and IL-7 × CCL19 results in enhanced antitumor efficacy.Virol J2022;19:74 PMCID:PMC9034647

[61] Huang F,Zhang Y,Wang Y.Development of molecular mechanisms and their application on oncolytic newcastle disease virus in cancer therapy.Front Mol Biosci2022;9:889403 PMCID:PMC9289221

[62] Krishna S,Copeland AR.Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer.Science2020;370:1328-34 PMCID:PMC8883579

[63] Dudley ME,Yang JC.A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma.J Immunother2002;25:243-51 PMCID:PMC2413438

[64] Albarrán V,Pozas J.Adoptive T cell therapy for solid tumors: current landscape and future challenges.Front Immunol2024;15:1352805 PMCID:PMC10972864

[65] Pedersen M,Milne K.Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study.Oncoimmunology2018;7:e1502905 PMCID:PMC6279323

[66] Verdegaal EME,Welters MJP.Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer.J Immunother Cancer2023;11:e007697 PMCID:PMC10649798

[67] Marofi F,Safonov VA.CAR T cells in solid tumors: challenges and opportunities.Stem Cell Res Ther2021;12:81 PMCID:PMC7831265

[68] Li YR,Yang L.Immune evasion in cell-based immunotherapy: unraveling challenges and novel strategies.J Biomed Sci2024;31:5 PMCID:PMC10785504

[69] Klampatsa A,Albelda SM.Mesothelin-targeted CAR-T cell therapy for solid tumors.Expert Opin Biol Ther2021;21:473-86

[70] Schoutrop E,Poiret T.Mesothelin-specific CAR T cells target ovarian cancer.Cancer Res2021;81:3022-35

[71] Chekmasova AA,Nikhamin Y.Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen.Clin Cancer Res2010;16:3594-606 PMCID:PMC2907178

[72] Frigerio B,Silvana C.Role of antibody engineering in generation of derivatives starting from MOv19 MAb: 40 years of biological/therapeutic tools against folate receptor alfa.Antib Ther2022;5:301-10 PMCID:PMC9743174

[73] Daigre J,Bethke M.Preclinical evaluation of novel folate receptor 1-directed CAR T cells for ovarian cancer.Cancers2024;16:333 PMCID:PMC10813853

[74] Zuo S,Panha H.Modification of cytokine-induced killer cells with folate receptor alpha (FRα)-specific chimeric antigen receptors enhances their antitumor immunity toward FRα-positive ovarian cancers.Mol Immunol2017;85:293-304

[75] Han C,Bellone S.The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo.Gynecol Oncol2023;170:172-8 PMCID:PMC10023457

[76] Jiang D,Sun H.Radiolabeled pertuzumab for imaging of human epidermal growth factor receptor 2 expression in ovarian cancer.Eur J Nucl Med Mol Imaging2017;44:1296-305 PMCID:PMC5471126

[77] Ma LS,Huang Y,Zhu YU.Downregulation of human epidermal growth factor receptor 2 by short hairpin RNA increases chemosensitivity of human ovarian cancer cells.Oncol Lett2015;9:2211-7 PMCID:PMC4467329

[78] Ferrara F,Capuozzo M.Atopic dermatitis: treatment and innovations in immunotherapy.Inflammopharmacology2024;32:1777-89

[79] Seifeddine R,Blanc E.Hypoxia down-regulates CCAAT/enhancer binding protein-alpha expression in breast cancer cells.Cancer Res2008;68:2158-65

[80] Altwerger G,Glazer PM.Harnessing the effects of hypoxia-like inhibition on homology-directed DNA repair.Semin Cancer Biol2024;98:11-8 PMCID:PMC10872265

[81] Henning W.Homologous recombination and cell cycle checkpoints: Rad51 in tumour progression and therapy resistance.Toxicology2003;193:91-109

[82] Zhuang Y,He Q,Jiang C.Hypoxia signaling in cancer: implications for therapeutic interventions.MedComm2023;4:e203 PMCID:PMC9870816

[83] Revythis A,Mikropoulos C.Recent insights into PARP and immuno-checkpoint inhibitors in epithelial ovarian cancer.Int J Environ Res Public Health2022;19:8577 PMCID:PMC9317199

[84] Giannone G,Genta S.Immuno-metabolism and microenvironment in cancer: key players for immunotherapy.Int J Mol Sci2020;21:4414 PMCID:PMC7352562

[85] Guerrouahen BS,Cugno C,Akporiaye ET.Reverting immune suppression to enhance cancer immunotherapy.Front Oncol2019;9:1554 PMCID:PMC6985581

[86] Wang Y,Ren Y,Yi P.Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer.Semin Cancer Biol2022;86:542-65

[87] Aliyuda F,Ghose A.Advances in ovarian cancer treatment beyond PARP inhibitors.Curr Cancer Drug Targets2023;23:433-46